The Curious Case Of Gleevec Pricing
As a branded drug, Gleevec ' s price increases were the target of criticism by oncologists, payers, and patients. Yet, its price was more reflective of value than many other cancer drugs. What is problematic is the fact that generic imatinib ' s list price has remained stubbornly high. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 12, 2018 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Source Type: news
OHSU's Druker wins prestigious award for developing Gleevec
The 2018 Tang Prize in Biopharmaceutical Science recognizes Druker for his pioneering role in precision medicine. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 19, 2018 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news
OHSU's Druker wins prestigious award for developing Gleevec
The 2018 Tang Prize in Biopharmaceutical Science recognizes Druker for his pioneering role in precision medicine. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 19, 2018 Category: American Health Authors: Elizabeth Hayes Source Type: news
Imatinib-induced Fulminant Liver Failure in CML Imatinib-induced Fulminant Liver Failure in CML
Acute liver failure can be a fatal adverse effect of chronic myeloid leukemia treatment with imatinib. Is liver transplant a viable option for these patients?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Cost Savings Limited With Generic Imatinib
WEDNESDAY, May 9, 2018 -- Prices of imatinib (Gleevec) remained high even after a generic version was introduced, according to a study published in the May issue of Health Affairs.
Ashley L. Cole, from the University of North Carolina at Chapel... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 9, 2018 Category: Pharmaceuticals Source Type: news
Generic Drugs Don't Always Push Prices Down
MONDAY, May 7, 2018 -- Generic drugs tend to trigger big drops in the cost of their expensive, brand-name counterparts, but that has not been the case with the cancer drug commonly known as Gleevec (imatinib).
There ' s been only a small drop in the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 7, 2018 Category: General Medicine Source Type: news
Generic options provide limited savings for expensive drugs
(Vanderbilt University Medical Center) Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 7, 2018 Category: Cancer & Oncology Source Type: news
Mylan launches generic version of Gleevec tablets in US
Mylan has launched the generic version of Novartis's Gleevec tablets, Imatinib Mesylate, in 100mg and 400mg versions in the US. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 1, 2017 Category: Pharmaceuticals Source Type: news
Imatinib a Double-Edged Sword for Pregnant CML Patients Imatinib a Double-Edged Sword for Pregnant CML Patients
On the one hand, imatinib keeps the CML in check; on the other hand, it carries a risk for fetal congenital malformation if taken during pregnancy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 19, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Imatinib shows increased survival in ICR ’s Phase III oncology trial
A Phase III clinical trial of imatinib (Glivec) conducted by UK researchers from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust demonstrated increased survival in patients with advanced gastrointestinal stromal tumo … (Source: Drug Development Technology)
Source: Drug Development Technology - August 20, 2017 Category: Pharmaceuticals Source Type: news
